Please sign in to follow a disease.
Does the clock matter? trial tests endoscopy timing for cirrhosis bleeding
NCT ID NCT06031402
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
People with liver cirrhosis can develop dangerous bleeding from swollen veins in the esophagus or stomach. Doctors use endoscopy to find and treat the bleeding, but they do not know the best time to do it. This trial randomly assigns patients to different endoscopy timings to see which approach controls bleeding better, prevents rebleeding, and improves survival. The study includes 368 adults with cirrhosis and suspected variceal bleeding.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- endoscopy, a camera procedure used to find and treat bleeding veins in the esophagus and stomach
- What this could lead to
- If one timing works better, doctors could have clearer guidance on when to perform endoscopy for cirrhosis patients with bleeding veins, which may improve bleeding control and survival.
- What could go wrong
- The trial may find no difference between timings, or the results may not apply to all patients. Endoscopy carries small risks such as fever, chest pain, swallowing problems, perforation, or pneumonia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 368 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. patients with AUGIB which is highly suspected to be caused by gastroesophageal variceal rupture; 2. patients with a diagnosis of liver cirrhosis based on imaging and pathology; 3. patients and/or their relatives who sign informed consents; 4. patients' age ≥18 years. Exclusion Criteria: 1. patients who have undergone endoscopy at other hospitals before admissions; 2. patients' hemodynamics are unstable after resuscitation; 3. patients with severe cardiovascular or cerebrovascular diseases or renal injury; 4. patients who have taken anticoagulants or antiplatelet drugs within 2 weeks before admissions, or are diagnosed with severe hematological diseases; 5. patients with human immunodeficiency virus or other acquired or congenital immune deficiency diseases; 6. patients with mental illness; 7. pregnancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute upper gastrointestinal bleeding are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
Shenyang, Liaoning, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.